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ABSTRACT 
A  dendrimer  can  described  as  a  macromolecule  characterized  by  its  highly  branched  3D  structure  which  provides  a  high  degree  of  surface  functionality  and  versatility 
Dendrimers also referred to as the “Polymers of the 21
st century.” Dendrimers components, namely (1) an initiator core (2) Interior layers (generations) composed of repeating 
units, radically attached to the interior core. (3) Exterior (terminal functionality) attached to the outermost interior generations. The properties of dendrimers are dominated by 
the functional groups on the molecular surface for example a dendrimer can be water soluble when its end group likes a carboxyl group. The major application of dendrimers 
are: Gene and oligonucleotide delivery, Targeting  of anticancer chemotherapy, As anti-infective agent, In vivo diagnostics, Targeted and Controlled release drug delivery, In 
photodynamic therapy, In industrial processes etc. Recent successes in simplifying and optimizing the synthesis of dendrimers provide a large variety of structures with reduced 
cost of their production. Also as research progresses, newer applications of dendrimers will emerge and the future should witness an increasing numbers of commercialized 
dendrimer based drug delivery systems. 
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Segment-block dendrimers, Layer-block dendrimers, Contrast agents, Delivery of drugs, Industrial processes.  
 
INTRODUCTION 
Dendrimers  are  repeatedly  branched  roughly  spherical  large 
molecules and posses well defined chemical Structures
1. The word 
Dendrimer comes from a Greek word which means to "tree". The 
other  synonyms  for  dendrimer  include  arborols  and  cascade 
molecules.  A  dendrimer  is  typically  symmetric  around  the  core 
(Fig.1), and often adopts a spherical three-dimensional morphology. 
In  the  view  of  polymer  chemistry  dendrimers  are  nearly  perfect 
monodisperse macro molecules with a regular highly branched three 
dimensional  structures  (Fig.3)  and  consists  of  three  architectural 
components like core, branches, and end groups
2,3. They are built 
from a starting atom, such as nitrogen, to which carbon and other 
elements  are  added  by  a  repeating  series  of  chemical  reactions 
(Fig.2) that produce a spherical branching structure
4.   
The three distinguished architectural components
 4,5 of a dendrimers 
are  namely 
(i) An initiator core. 
(ii)  Interior  layers  (generations)  composed  of  repeating  units, 
radically attached to the interior core. 
(iii)  Exterior  (terminal  functionality)  attached  to  the  outermost 
interior generations. 
TYPES OF DENDRIMERS  
1. PAMAM Dendrimer 
Poly  (amidoamine)  dendrimers (PAMAM)  are  synthesized  by  the 
divergent  method  starting  from  ammonia  or  ethylenediamine 
initiator  core  reagents.  They  are  constructed  using  a  reiterative 
sequence  consisting  of  (a)  a  double  Michael  addition  of  methyl 
acrylate to a primary amino group followed by (Fig.4) (b) amidation 
of the resulting carbomethoxy intermediate with a large excess of 
ethylenediamine.  
2. PAMAMOS Dendrimer 
Radically  layered  poly  (amidoamine-organosilicon)  dendrimers 
(PAMAMOS)  are  inverted  unimolecular  micelles  that  consist  of 
hydrophilic, nucleophilic polyamidoamine (PAMAM) interiors and 
hydrophobic  organosilicon  (OS)  exteriors
8.  These  dendrimers  are 
exceptionally useful precursors for the preparation of honeycomb-
like networks with nanoscopic PAMAM and OS domains
9. 
3. PPI Dendrimer 
Poly  (propylene  imine)  dendrimers  (PPI)  are  synthesized  by  the 
divergent method starting from 1, 4-diaminobutane. They are grown 
by a reiterative sequence consisting of (a) a double Michael addition 
of  acrylonitrile  to  the  primary  amino  groups  followed  by  (b) 
hydrogenation  under  pressure  in  the  presence  of  Raney  cobalt. 
Products are made up to generation
10. 
4. Tecto Dendrimer 
These are composed of a core dendrimer, surrounded by dendrimers 
of several steps (each type design) to perform a function necessary 
for a smart therapeutic nanodevice. Different compounds perform 
varied functions ranging from diseased cell recognition, diagnosis of 
disease state drug delivery, reporting location to reporting outcomes 
of  therapy.  Tecto-dendrimers  are  composed  of  a  core  dendrimer 
(Fig.5),  which  may  or  may  not  contain  the  therapeutic  agent, 
surrounded  by  dendrimers.  The  surrounding  dendrimers  are  of 
several types, each type designed to perform a function necessary to 
a smart therapeutic nanodevice
10. 
5. Multilingual Dendrimer 
In these dendrimers, the surface contains multiple copies (Fig.6) of a 
particular functional group
11. 
6. Chiral Dendrimer 
The chirality in these dendrimers are based upon the construction of 
a constitutionally different but chemically similar branches (Fig.7) to 
chiral core
12. 
7. Hybrid Dendrimers linear polymer 
These are hybrids (block or graft polymers) of dendritic and linear 
polymers
12. 
8. Ampiphilic Dendrimer 
They are built with two segregated sites of chain end (Fig.8), one 
half is electron donating and the other half is electron withdrawing
13.   
9. Micellar Dendrimer 
These  are  unimolecular  micelles  (Fig.9)  of  water  soluble  hyper 
branched polyphenylenes
13. 
SYNTHESIS OF DENDRIMERS 
Dendrimers can contain three major portions, The core, inner shell 
and  outer  shell  generally  dendrimers  can  synthesized  to  exhibit  
different functionality in each of these portions, to control physical 
properties  such  as  solubility,  thermal  stability,  and  attachment  of 
compounds for particular applications. With the help of Synthetic 
methods  (Fig.10)of  dendrimers  synthesis  can  precisely  control  the 
size and number of branches on the dendrimer
13. 
There are two defined methods of dendrimer synthesis 
1.  Divergent synthesis  
2.  Convergent synthesis 
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Divergent Method 
This  is  mechanical  reaction.  The  dendrimer  is  assembled  from 
multifunctional  core,  which  is  extends  outward  by  a  series  of 
reactions (Fig.11), Each step of the reaction must be driven to full 
completion to prevent mistakes in the dendrimer, which can cause 
trailing  generations  (some  branches  are  shorter  than  the  others). 
Such impurities can impact the functionality and symmetry of the 
dendrimer,  but  are  extremely  difficult  to  purify  out  because  the 
relative size difference between perfect and imperfect dendrimers is 
very small
14. 
Convergent Method 
Dendrimers generally made of small molecules that end up at the 
surface of the sphere and reactions proceed inward and are evenly 
attached to the core this method (Fig.12) makes it much easier to 
remove impurities and shorter branches along the way, so that the 
final dendrimer is more monodisperse
14. 
APPLICATION OF DENDRIMERS IN DRUG DELIVERY  
A successful drug must perform the demanding tasks of selectively 
recognizing  and  binding  to  a molecular  target,  then triggering an 
appropriate  biological  response,  all  the  while  possessing 
pharmacological  properties  that  render  it  ‘‘drug-like’’
14.  In  some 
cases, nature has supplied compounds – such as aspirin or penicillin 
– that can be used directly as drugs but the more common situation 
is  that  many  otherwise  promising  therapeutic  agents  are  not 
successful  in  the  clinic  because  of  their  poor  pharmacological 
properties
15. The properties of dendrimers, in particular the synthetic 
ability  to  provide  them  with many  diﬀerent  biological  properties, 
along with their capacity to carry conjugated surface molecules or 
encapsulated guest molecules, make them immediately attractive as 
potential  vehicles  (Fig.13)  for  drug  delivery
16,17.  Dendrimers  have 
emerged  as  promising  nanoscale  delivery  vehicles  for 
targeted delivery  of  drugs and  imaging  agents
18.  Dendrimer-
drug conjugates  have  been  investigated  for  oral,  parenteral ocular 
transdermal colon and  topical  routes  of  administration
19.  The 
Dendrimer-drug conjugates are designed to carry therapeutic agents 
to specific tissues to reduce systemic effects and increase efficacy at 
the targeted sites
20.  
Researchers are working to convert dendrimers like these into useful 
drug-delivery tools. But dendrimers are already widely used in the 
lab. Qiagen's Superfect DNA transfect ion reagent is a dendrimer 
whose positively charged surface binds the nucleic acids negatively 
charged phosphate backbone. 
If  Dendrimer-drug conjugates  can  be  designed  to  be  confined  to 
either  maternal  or  fetal  compartments,  there  will  be  significant 
therapeutic benefits
21. The success  of this strategy depends on the 
stability and specificity of the conjugate in the body as it reaches the 
target site (or, target tissue) with subsequent release of drugs before 
the  conjugate  is  eventually  cleared  from  the  body
22.  The  release 
drugs  from  the  dendrimer  conjugate  is  often  slow  and  is  largely 
governed by the nature of linking chemistry  and the release of drugs 
from  dendrimers conjugates  can  be  modulated  by  choice  of 
appropriate  spacer  or  linker  to  avoid  release  in  physiological 
conditions  such  as blood or plasma and  to  trigger  release  at  the 
target  site
23.  Interestingly,  this  criterion  is  not  essential  in  all 
instances, and some dendrimer conjugates exhibit efficacy in their 
conjugated  forms.  The  dendrimer biodistribute      rapidly  and  are 
localized in major organs within minutes of administration
24. The 
inability to control passage of small drug molecules across human 
placenta has been accepted
25.  
However progress towards achieving safe and selective drug therapy 
during pregnancy by proper drug design and development has not 
been undertaken. The ability to design biocompatible. Dendrimer-
drug conjugates that rapidly biodistribute, are stable during retention 
in circulation, and release the drug only at a targeted site suggests a 
possible  mechanism  to  avoid  the  undesirable  transfer  of  certain 
small drug molecules to fetus, which could be toxic to the concepts. 
The benefits and safety of drugs conjugated to the dendrimers and 
administered to the pregnant woman and unborn fetuses are yet to be 
studied
26.  The  present  study  describes  the ex-vivo transport  and 
biodistribution  of dendrimer  conjugates  in  the  dually 
perfused human placental  lobule
27.  This  study  also  develops  the 
potential for use of polymer–drug conjugates as delivery vectors to 
selectively treat the mother without affecting the fetus
 28. 
Drug delivery eﬀorts are complicated by the diversity of molecules 
that hold potential therapeutic or diagnostic value briery reviewing 
three classes of drug candidates based on size demonstrates the wide 
applicability to drug delivery
29. First, regarding ‘‘small molecules’’, 
many  low  molecular  weight  drug  candidates  are  limited  by  poor 
solubility in aqueous environments or, if they are soluble, face rapid 
elimination from the bloodstream through ﬁltration in the kidney
30. 
In the past, eﬀorts have been made to modify the molecule itself, 
often following the ‘‘rule-of-ﬁve’’ guidelines developed by Lipinski 
to  raise  awareness  of  the  properties  and  structural  features  that 
render molecules more or less ‘‘drug-like. Dendrimers present an 
attractive  alternative  strategy  to  the redesign  of  the  drug because 
they  allow  unfavorable  properties  of  a  small  molecule,  such  as 
insolubility,  to  be  overcome  by  the  larger  characteristics  of  the 
macromolecule
31. An approach for improving the pharmacological 
properties of higher molecular weight drug candidates, analogous to 
Lipinski’s guidelines for the modiﬁcation of small molecule drugs, 
has  been  applied  for  protein  therapeutics  such  as  recombinant 
antibodies  and protein  toxins  used in  cancer  treatment
32. In  these 
cases, the amino acid sequences of recombinant proteins have been 
‘‘humanized’’ by genetic engineering to avoid immunogenicity  and 
their glycosylation patterns have been modi- ﬁed to increase serum 
half-life
33.  
These  eﬀorts,  undertaken  with  actual  proteins,  illuminate  design 
features  that  can  beneﬁt  the  development  of  protein
  mimics, 
dendrimers
34.  In  particular,  the  ‘‘humanizing’’  experiments  show 
that small changes, such as the substitution of a single amino acid 
for another, can avoid signiﬁcant problems like undesired systemic 
immune responses. In the same manner, small changes in the surface 
properties  of  dendrimers,  such  as  the  addition  of  poly(ethylene 
glycol) (PEG), can avoid unwanted immunogenicity
35. Finally, even 
extremely large therapeutic candidates, notably plasmids or naked 
viral DNAs used for non-viral gene delivery that are well beyond the 
size of traditional drugs, are also beneﬁting from dendrimer-assisted 
delivery
36.      Dendrimers  have  ideal  properties  which  are  useful 
targeted  drug  delivery  system.  One  of  the    most  effective  cell 
specific  targeting  agents  delivered  by  dendrimers  is  folic  acid 
PAMAM  dendrimers  modified  with  carboxymethyl  PEG5000 
surface chains revealed reasonable drug loading a reduced release 
and reduced hemolytic toxicity compared with the non-PEGylated  
dendrimer  A third-generation dendritic  unimolecular micelle with  
indomethacin entrapped as model drug gives  slow and sustained in 
vitro release, as  compared to cellulose membrane control
37,38,39 . 
Controlled  release  of  the  Flurbiprofen  could  be  achieved  by 
formation  of  complex  with  amine  terminated  generation  4  (G4) 
PAMAM  Dendrimers.  The  results  found  that  PEG-dendrimers 
conjugated  with  encapsulated  drug  and  sustained  release  of 
methotrexate as compare to unencapsulated drug
39,40. In control drug 
release  dendrimers  act  as  the  anticancer  drugs  adriamycin  and 
methotrexate were encapsulated into PAMAM dendrimers (i.e. G=3 
and 4) which had been modified with PEG monomethyl ether chains 
(i.e.  550  and  2000  respectively)  attached  to  their  surfaces
41.  A 
similar  construct  involving  PEG  chains  and  PAMAM  dendrimers 
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of 5-  fluorouracil into G=4 Dendrimers in gene delivery increase in 
the  cytotoxicity  and  permeation  of  dendrimers  Dendrimer-based 
transfixion agents have  become routine tools for many molecular 
and  cell  biologist’s  dendrimers  are  extensively  used  as  non-viral 
vector for gene delivery
42. The use of dendrimers as gene transfixion 
agents  and  drug-delivery  devices  have  been  extensively  reviewed 
part
43. Various polyatomic compound such as a PEI, polylysine, and 
cationic have been utilized as non-viral gene carrier
44. 
Nanoparticle uptake from the gut is important as an additional route 
of entry into systemic circulation (Fig.14) and the translocation of 
particular  substance  across  gastro  intestinal  track  is  now  well 
documented phenomena offering new potential for the delivery of 
drugs  even  with  the  very  poor  dissolution  profiles  and  label 
chemistries via encapsulation in bio degradable nano particles
 46-51. 
Researchers stated that in the last few years have seen acceleration 
in the number of publications describing the varying facets of this 
approach and the multidisciplinary nature of this field
53. This review 
delineates data from this rather fragmented area and from cognate 
fields to provide a physicochemical viewpoint of the importance of 
surface  chemistries  of  oral  drug  delivery  vehicles  and  their 
interactions  in  and  with  gut  contents  prior  to  uptake
56.  Evolving 
vistas include a better understanding of the plasticity of the intestinal 
epithelium and M-cell induction as well as the influence of disease 
states  on  particulate  uptake.  In  this  review  we  address  a  number 
issues deemed vital to an understanding of the subject including (i) 
some background knowledge on particulate uptake (the subject of 
several reviews), (ii) factors affecting uptake such as diameter and 
surface  charge  and  character,  (iii)  the  dynamic  nature  of  particle 
interactions in the gut, (iv) the dynamic nature of the processes of 
capture, adhesion, uptake, transcytosis and translocation, and (v) the 
influence of surface Ligands
61-62. 
There is now a growing importance using dendrimers in drug, gene 
and vaccine delivery and according modern studies dendrimers are 
also  using  as therapeutic  agents
63.  The  oral absorption  and  organ 
distribution of some dendrimers has been studied and the structure 
and  size-related  toxicity  and  biocompatibility  of  many  types  of 
dendrimers is being actively researched
64. Interaction of dendrimers 
with other drugs and dyes providing potential applications in areas 
such as the solubilisation of hydrophobic molecules and molecular 
inclusion  formation
65.  Dendrimers  have  been  designed  to  act  as 
nanoscopic containers or dendrite boxes and unimolecular micelles 
and  reverse  molecular  micelles  have  been  described.  Dendrimers 
have  been  variously  proposed  as  pH-sensitive  controlled  drug 
release  systems,  catalysts  and  as  chromatographic  materials
66. 
Dendrimers posses unique characteristics including monodispersity 
and modifiable surface functionality  including highly defined size 
and  structure,  these  ideal  characteristics  of    dendrimers  makes 
polymers  attractive  candidates    as  carrier  in  drug  delivery 
applications. Drug delivery can be achieved by coupling a drug to 
polymer through one of two approaches
67.  
Dendrimer attached to the cell membrane, dendrimer conjugation to 
DNA  Standard  Hydrophobic  drugs  can  be  complexed  within  the 
hydrophobic dendrimer interior to make them water-soluble or drugs 
can be covalently coupled onto the surface of the dendrimer.  Using 
both  methods  in  this  study  the  experiment  conducting  team 
compared the efficacy of generation 5. 
PAMAM dendrimers in the targeted drug delivery of methotrexate 
coupled to the polymer
 68. The amine-terminated dendrimers bind to 
negatively charged membranes of cells in a non-specific manner and 
can cause toxicity in vitro and in vivo. To reduce toxicity and to 
increase aqueous solubility, modifications were made to the surface 
hydroxyl groups of the dendrimers. For targeted drug delivery, the 
dendrimer was modified to have a neutral terminal functionality for 
use with surface-conjugated folic acid as the targeting agent. The 
complexation of methotrexate within a dendrimer changes the water 
insoluble  drug  into  a  stable  and readily  water-soluble  compound. 
When  this  dendrimer  complexed  drug, however,  was  placed  in a 
solution  of  phosphate  buffered  saline,  the  methotrexate  was 
immediately  released  and  displayed  diffusion  characteristics 
identical  to  free  methotrexate.  Covalently  coupled  methotrexate 
dendrimer conjugates were stable under identical conditions in water 
and buffered saline. Cytotoxicity tests showed that methotrexate as 
the dendrimer inclusion complex had an activity identical to the free 
drug  in  vitro.  In  contrast,  folic  acid  targeted  dendrimer  with 
covalently  conjugated  methotrexate  specifically  killed  receptor-
expressing  cells  by  intracellular  delivery  of  the  drug  through 
receptor-mediated endocytosis. This study demonstrates that while 
drug as a dendrimer inclusion complex is readily released and active 
in vitro, covalently conjugated drug to dendrimer is better suited for 
specifically targeted drug delivery
 69-72.  
Example 
Dendrimer  would  be  limited  in  their  transfer  across 
the human placenta when  compared  to  smaller  drug molecules 
alone,  suggesting  novel  methods  for  selectively  delivering 
therapeutics  to  the  pregnant  woman  (Fig.15)  without  significant 
transfer to the fetus, especially since the half life of the dendrimers 
in blood is relatively short
71. 
APPLICATION OF DENDRIMERS FOR GENE DELIVERY 
Delivery  vectors  for  intracellular  delivery  of  nucleic  acids.  Apart 
from  viruses,  synthetic  cationic  vectors  (Fig.16)  such  as  cationic 
polymers, branched dendrimers, cell-penetrating (CP) peptides and 
cationic liposomes can be used to deliver genes into cells. Properties 
of an engineered synthetic vector for gene therapy in the future. In 
addition to exhibiting good biocompatibility, loading capacity and 
transfection  efficiency,  a  future  synthetic  vector  may  also  be 
designed to have a desired intrinsic biological activity that would 
enhance the effects of gene therapy. 
The delivery of small molecules complexed as guest molecules in 
internal  void  spaces  of  dendrimers  is,  at  least  in  retrospect, 
intuitively  obvious.  By  contrast,  the  delivery  of  extremely  large 
macromolecules,  such  as  MDa-sized  plasmid  DNA  for  non-viral 
gene  therapy,  is  counter-intuitive  because  the  encapsulation  of  a 
‘‘guest’’  molecule  many  times  the  molecular  weight  of  the 
dendrimer itself appears impos-Dendrimers in Cancer Treatment and 
Diagnosable. Nonetheless, experimental evidence had demonstrated 
that  gene  delivery  (Fig.17)  strategies  also  beneﬁt  from  the 
participation of dendrimers. For example, from its original discovery 
of eﬃcacy for gene delivery, the fractured form of PAMAM, known 
as Superfect TM is now a commercially-available transfection agent 
for in vitro applications. Typical approaches to optimize dendritic 
gene delivery for in vivo use have involved the surface modiﬁcation 
of a PAMAM backbone, either with arginine or hydroxyl groups. 
Alternatively,  the  results  reported  by  Kim  and  coworkers,  who 
demonstrated improved gene delivery with a novel PAMAM-PEG-
PAMAM triblock copolymer, show that construction of dendrimers 
composed of new building blocks is warranted . Although still in 
their infancy, there are eﬀorts afoot to  exploit dendrimers for the 
delivery of smaller nucleic acids such as antisense oligonucleotides 
and  short  interfering  RNAs  (siRNA);  the  success  of  these 
applications is likely to depend on the continuing development of 
novel materials for dendrimer synthesis
 75. 
APPLICATION OF DENDRIMERS AS ‘‘PRO-DRUGS’’ 
Once  a  dendrimer  carrying  an  encapsulated  drug  reaches  the 
intended  site  of  action,  the  guest  molecule  generally  must  be 
released to gain bioactivity. Indeed, a concern is that the active drug 
would  ‘‘leak’’  out  prematurely,  thereby  reducing  the  amount 
available  for  the  intended  therapeutic  intervention,  or  more 
ominously,  result  in  systemic  toxicity.  Reassuringly,  early Bhattacharyya Sayani et al. IRJP 2011, 2 (9), 25-32 
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY, 2(9), 2011 
experiments showed that the close packing of dendritic branches on 
the surface of the macromolecule effectively formed a ‘‘membrane’’ 
that reduced diﬀusion to immeasurably slow rates. In other cases, 
the  release  of  encapsulated  guest  molecules  was  relatively  faster, 
occurring  over  a  few  hours,  apparently  through  hydrolytic 
degradation of the dendrimer in aqueous conditions. The observation 
that  guest  molecules  could  be  liberated  at  diﬀerent  rates 
demonstrated that viable opportunities exist to tailor the release for 
either slow or rapid delivery.  
At present, additional control of delivery rates is being sought; for 
instance,  the  ability  of  a  dendrimer  to  instantaneously  release  its 
entire  drug  payload  upon  reaching  its  cellular  target  would  be 
valuable. Promising steps in this direction are being taken by the 
development of pH-sensitive materials, the ﬁne tuning of hydrolytic 
release conditions, and the selective liberation of guest molecules on 
the basis of their size or shape. 
PHARMACEUTICAL APPLICATIONS 
Dendrimer as Solubility Enhancers 
Solubility  is  very  important  factor  in  drug  delivery,  on  the  other 
hand  there  are  many  drugs  with  very  strong  therapeutic  activity 
these  are  not  able  use  due  to  poor  solubility  properties.  Water 
soluble dendrimers (Fig.19)are capable of  binding and solubilizing 
small acidic hydrophobic molecules with antifungal or antibacterial 
properties,  because  dendrimers  posses  hydrophobic  core  and 
hydrophilic surface layer. This characteristic offers the opportunity 
to soluble poorly soluble drugs by  encapsulating them within the 
dendritic structure at all concentrations of dendrimer. 
Example 
A  hydrophilic–hydrophobic  core-shell  dendrimer  with  PAMAM 
interior  and  long  alkane  chain  exterior  was  shown  to  bind  5-
flurouracil,  a  water-soluble  anti-tumor  drug .After  phospholipid 
coating  of  the  dendrimer–fatty-  acid  macromolecule,  oral 
bioavailability in rats of 5-flurouracil was nearly twice the level of 
free  5-flurouracil  .  Dendrimer-based  carriers  could  offer  the 
opportunity  to  enhance  the  oral  bioavailability  of  problematic 
drugs
74.  
Cellular Delivery Using Dendrimer Carriers 
According to Kannan et al. the dynamics of cellular entry into A549 
human  lung  epithelial  carcinoma  cells  of  a  range  of  PAMAM 
dendrimers (G4-NH2, G3-NH2, G4-OH, PEGlayted G3 [G3-PEG]) 
and a hyper branched polymer (polyol). G4-NH2and G4-OH entered 
cells  more  rapidly  than  did  G3-NH2,  polyol  or  G3-PEG.  It  was 
suggested that the rapid entry of G4-NH2 might be a result of the 
cationic  nature  of  the  amine  surface  groups,  which  may  interact 
electro statically with negatively charged epithelial cells and enter 
via ﬂuid phase pinocytosis. The lower rate of cellular entry of G3-
NH2com-pared  with  G4-NH2may  be  a  result  of  fewer    surface 
charges on the G3-NH2dendrimer.Because polyol and G3-PEG do 
not have cationic surface groups, their cellular entry may result from 
non-speciﬁc  adsorption  to  the  cell  membrane  and  subsequent 
endocytosis.  Dendrimer–ibuprofen  complexes  entered  the  cells 
rapidly compared with pure drug (1 hr versus>3 hr), suggesting that 
dendrimers can efficiently carry (Fig.20) the complexed drug inside 
cells.  PAMAM  dendrimers  were  surface-engineered  with  lauryl 
chains to reduce toxicity and enhance cellular uptake
75. 
Dendrimers as Nano-Drugs 
By  modifying  Poly(lysine)  dendrimers  with  sulfonated  naphthyl 
have been found to be useful as antiviral drugs against the herpes 
simplex  virus  can  potentially  prevent/reduce  transmission  of  HIV 
and other sexually transmitted diseases (STDs). The early studies 
suggest that PAMAM dendrimers covalently modified with naphthyl 
sulfonate  residues  on  the  surface  also  exhibited  antiviral  activity 
against HIV. This dendrimer-based nano-drug inhibited early stage 
virus/cell adsorption and later stage viral replication by interfering 
with reverse transcriptase and/or integrate enzyme activities. On the 
other  hand  PPI  dendrimers  with  tertiary  alkyl  ammonium  groups 
attached to the surface have been shown to be potent antibacterial 
biocides against Gram positive and Gram negative bacteria
76. 
Dendrimers In Photodynamic Therapy 
The photosensitizer 5-aminolevulinic acid has been attached to the 
surface  of  dendrimers  and  studied  as  an  agent  for  PDT  of 
tumorigenic  keratinocytes  .Photos  ensitive  dyes  have  been 
incorporated  into  dendrimers  and  utilized  in  PDT  devices.  This 
cancer  treatment  involves  the  administration  of  a  light-  activated 
photosensitizing drug that selectively concentrates in diseased tissue. 
The possibility of improving the properties of dendrimers through 
appropriate unfunctionalization of their periphery makes dendrimers 
promising carriers for photosensitizers
82.  
NON-PHARMACEUTICAL APPLICATIONS 
Diagnostics 
Paramagnetic  metal  chelates  such  as  Gd(III)-  N,N’,N’’,N”’-
tetracarboxymethyl-1,4,7,10-tetraazacy-clododecane  (Gd(III)-
DOTA),  Gd(III)-diethylenetri-  amine  pent  acetic  acid  (Gd(III)-
DTPA), and their derivatives used as contrast agents for magnetic 
resonance imaging (MRI). 
The (Gd(III)-DTPA) conjugate (MagnevistR) (Schering AG) and is 
a  widely  used  MRI  contrast  agent.  In  another  approach,  the 
conjugation of (Gd(III)-DOTA) to poly(l-glutamic acid) (molecular 
weight  50  kDa)  via  the  biodegradable  disulfide  spacer  cystamine 
was  studied  to  find  a  safe  and  effective  macromolecular  MRI 
contrast  agent.  Consequently,  dendrimer-based  Gd(III)  chelates 
consisting of generations 2 and 6 PAMAM dendrimers with 12 and 
192 terminal surface amines conjugated to the chelating ligand 2-(4-
isothiocyanatobenzyl)-6-  ethyldiethylenetriamine-  pent  acetic  acid 
through a thio urea linkage were synthesized .These contrast agents 
exhibited excellent MRI images of blood vessels upon intravenous 
injection.  These  dendrimer  polychelates  were  exploited  for  high-
quality MR angiography (MRA) images up to 60 min post injection. 
DNA-dendrimers,  which  are  constructed  for  routine  use  in  high-
throughput functional genomic analysis, and as biosensors for the 
rapid diagnosis have genetic, and pathogenesis diseases
 77. 
Dendritic Catalysts / Enzymes/ 
Dendrimers have a multifunctional surface and all catalytic sites are 
always exposed towards the reaction mixture. They can be recovered 
from  the  reaction  mixture  by  easy  ultra  filtration  methods
39. 
Dendritic shells can be used to create a microenvironment favorable 
for  catalysis  or  provide  shielding  for  functional  groups  at  the 
dendritic core. Because of their ‘pseudo’-spherical nature and their 
resultant  conformations  the  metal  sites  in  these  well-deﬁned 
polymeric  catalysts  should  be  easily  accessible  for  substrate 
molecules  and reagents, and  therefore  exhibit  characteristics-  fast 
kinetics, speciﬁcity and solubility
 40. 
1. Metallodendritic catalysts 
2. Catalysis with phosphine-based dendrimers 
3. Catalysis with (metallo) dendrimers containing chiral ligands 
4. Non-metal containing dendrimers 
Industrial Processes  
Dendrimers can encapsulate insoluble materials, such as metals, and 
transport them into a solvent within their interior. Cooper and co-
workers  synthesized  fluorinated  dendrimers,  which  are  soluble  in 
supercritical  CO2 and  can  be  used  to  extract  strongly  hydrophilic 
compounds  from  water  into  liquid  CO2.  This  may  help  develop 
Technologies in which hazardous organic solvents are replaced by 
liquid CO2
80
. 
CONCLUSION 
Although the application of dendrimers in the field of drug, gene, 
and  vaccine  delivery  is  in  its  infancy,  dendrimers  offer  several 
attractive features, including the control one has over the primary Bhattacharyya Sayani et al. IRJP 2011, 2 (9), 25-32 
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY, 2(9), 2011 
nature of the system. They provide a platform for the attachment of 
drugs  or  genes  and  their  release  through  several  mechanisms. 
Dendrimers  can  be  endowed  with  many  favorable  properties  for 
drug delivery, an ultimate challenge – ergo, a ‘real-world’’ test – of 
these versatile nano-devices will be whether they can successfully 
meet the formidable tasks of diagnosing and treating of malignant 
disease.  Although  signiﬁcant  work  remains  in  several  areas, 
prospects  now  appear  bright  for  dendrimer-based  approaches  to 
cancer treatment
84-88. 
 We  have  not  discussed  here  the  toxicity  of  the  systems  simply 
because the range of materials is so great, and one cannot generalize. 
Obviously,  the  toxicity,  biodegradability,  and  biocompatibility  of 
dendrimers and dendrons have to be explored for each system and 
each application, but this should not inhibit research in the area. The 
most interesting and valuable systems are yet to come. 
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Fig.1. Basic components of Dendrimer 
 
 
 
 
Fig.2. Dendrimer at different concentrations (a) Dilute (b) Contact (c) Collapse (d) 
Interpenetrate 
 
 
 
Fig.3. Structure of Dendrimer 
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Fig.4. Synthesis of commercially available PAMAM dendrimer 
 
 
 
Fig.5. Structure of Tecto-Dendrimer and Standard Tecto-Dendrimer 
 
 
 
 
Fig.6. Structure of Multilingual dendrimer 
 
 
 
 
Fig.7. Separate dendritic catalysts from reaction mixtures at the end of the reaction by 
simple physical processes such as ultrafiltration as a consequence of the nanosize 
dimensions of dendrimers. 
 
 
 
Fig.8. Structure of Ampiphilic Dendrimer 
 
 
Fig.9. Structure of Micellar Dendrimer 
 
 
Fig.10. Construction of Dendrimers 
 
Fig.11. Divergent Dendrimer growth 
 
 
Fig.12. Convergent Dendrimer growth 
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Fig.13. Dendrimers as drug delivery tools 
 
 
 
Fig.14. Dendrimers as drug carriers  in nanotechnology 
 
 
 
Fig.15. Drug therapy for pregnant woman 
 
 
Fig.16. Delivery of vectors for intracellular delivery of nucleic acids. 
 
 
Fig.17. Dendrimer involved in gene transfection 
 
 
Fig.18. DNA molecules used to assemble nanoparticles in dendrimers 
 
 
 
Fig.19. Dendrimers as Potential Solubility Enhancers for Drugs 
 
Fig.20. Schematic of nanosystems that may function as combined drug delivery and 
imaging agents for targeting T cells: (A) liposomal systems, (B) solid biodegradable 
nanoparticulates, and (C) macromolecular dendrimer complexes. PEG indicates 
polyethylene glycol; Gd-DTPA, gadolininum-diethylene triamine pentaacetic acid. 